Our Pharma Insights Blog
In 2025, the US FDA approved 11 New Biological Entities (NBEs), representing a significant milestone…
In 2025, the US FDA approved 45 new drugs, including 34 New Chemical Entities (NCEs)…
In pharmaceutical development, choosing the right regulatory pathway can significantly influence timelines, costs, and overall…
Every breakthrough medication starts somewhere. That somewhere is either a New Chemical Entity (NCE) or…
Reference Listed Drugs (RLD): What they are and why RLD sourcing matters in generic drug development
When developing a generic drug, one of the critical steps is identifying and sourcing the…
Biosimilars and generics are both affordable alternatives to brand-name medications. These drugs play a crucial…
The year 2024 proved to be a turning point for pharmaceutical innovation. From oncology to…
When it comes to drugs, one of the most common questions patients ask is, Are…
Serialization was once a regulatory checkbox. Today, it’s the backbone of compliant, efficient, and transparent clinical…
This article, authored by our Founder Salim Shaikh in International Clinical Trial Magazine, explores how…
Generic drugs are essential to global healthcare, making treatments more affordable and accessible to the…
LSPedia, a leading provider of pharmaceutical compliance, serialization, and supply chain software solutions, today announced…